GlassScriptPhysician profile
Marc B Hazan
NPI 1952413809
$2,010.05
in general payments reported to CMS, 2019-2025
21 companies · $532 in 2025
The $532 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.30 · 2021: $80.58 · 2022: $300 · 2023: $409 · 2024: $612 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,535 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,534.67 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $289.91 | 2024-2025 | |
| Boston Scientific Corporation | $275.78 | 2022-2024 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $264.15 | 2023-2025 | Jardiance |
| Edwards Lifesciences Corporation | $222.62 | 2025 | Sapien 3 Ultra Resilia |
| Medtronic, INC. | $170.98 | 2023 | Cobalt Dr Mri Surescan |
| Merck Sharp & Dohme LLC | $144.78 | 2021-2025 | Capvaxive, Gardasil 9 |
| E.R. Squibb & Sons, L.L.C. | $117.71 | 2023 | Camzyos |
| Abbott Laboratories | $114.92 | 2024 | Cardiomems |
| Janssen Pharmaceuticals, INC | $83.82 | 2021-2022 | |
| Novo Nordisk INC | $44.66 | 2024-2025 | Wegovy |
| Atricure, INC. | $39.47 | 2019 | |
| Sanofi-Aventis U.S. LLC | $36.83 | 2019 | |
| Pfizer INC. | $36.27 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.61 | 2024 | |
| Medicomp INC | $27.43 | 2024 | Telepatch Cardiac Monitor |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $25.03 | 2025 | Gemtesa |
| Glaxosmithkline, LLC. | $22.40 | 2025 | Trelegy Ellipta |
| Exeltis, USA INC. | $17.93 | 2024 | Slynd |
| Esperion Therapeutics, INC. | $16.98 | 2024 | Nexletol |
| Inspire Medical Systems, INC. | $16.61 | 2025 | Inspire |
| Kowa Pharmaceuticals America, INC. | $13.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Hazan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.